Changchun High-tech: Approval Granted for Subsidiary GenSci155 Injection’s Domestic Production Clinical Trial Application for Drug Registration within China

Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the domestic registration clinical trial application for GenSci155 injection. GenSci155 injection is an independently developed long-acting fatty acid conjugated recombinant human insulin-like growth factor-1 (IGF-1) analog, intended for the prevention of bronchopulmonary dysplasia (BPD) in preterm infants and acute ischemic stroke (AIS).
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned